GT
FATE icon

Glenmede Trust’s Fate Therapeutics FATE Stock Holding History

Glenmede Trust’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-9,245
Closed -$207K – 1302
2022
Q3 		$207K Buy
+9,245
New +$267K ﹤0.01% 1079
2020
Q4 		– Sell
-742
Closed -$29K – 1559
2020
Q3 		$29K Buy
742
+712
+2,373% +$24.9K ﹤0.01% 1470
2020
Q2 		$1K Buy
+30
New +$894 ﹤0.01% 2320
2019
Q1 		– Sell
-1,070
Closed -$13 – 3087
2018
Q4 		$13 Buy
+1,070
New +$14.9K ﹤0.01% 2169
2018
Q3 		– Sell
-3,420
Closed -$39K – 1573
2018
Q2 		$39K Buy
+3,420
New +$37.7K ﹤0.01% 1525

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return